The Open Hand Initiative: Advancing Real-World Evidence in Medical Device Approvals

The Open Hand Initiative: Facilitating the Use of Real-World Evidence in Regulatory Submissions Through Collaboration and Transparency

The Open Hand Initiative, led by MDIC in collaboration with the FDA and industry partners, showcases a groundbreaking approach to using real-world data (RWD) and real-world evidence (RWE) in regulatory submissions. Piloted during the COVID-19 pandemic, this initiative brought together stakeholders to openly share insights and address challenges in transitioning SARS-CoV-2 diagnostics from Emergency Use Authorization (EUA) to full FDA approval.

By fostering transparency and collaboration, the Open Hand Initiative highlights best practices for leveraging high-quality RWD to generate RWE and streamline regulatory decision-making. Discover how this innovative model is shaping the future of medical device approvals and advancing patient care.

The Open Hand Initiative: Facilitating the Use of Real-World Evidence in Regulatory Submissions Through Collaboration and Transparency was published in the Clinical Pharmacology & Therapeutics Journal in Spring 2024.

More Like This

IVD RWE Education Series Module 1: Application of the MDIC IVD RWE Framework

Study Design Blueprint for Evaluating Analytical Performance Characteristics of Point of Care In Vitro Diagnostic Devices with Capillary Whole Blood (Fingerstick) Specimens

SRS Landscape Analysis Report